SCHEMBL544191

SCHEMBL544191

Cc1cccc(Cl)c1S(=O)(=O)Oc1ccc2nc(NC(=O)C3CC3)sc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 5/20 0.60
CASP3 P42574 1/20 0.55
SENP8 Q96LD8 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SENP6 Q9GZR1 1/20 0.55
ABL1 P00519 3/20 0.55
MAPT P10636 3/20 0.52
HTT P42858 2/20 0.52
LMNA P02545 1/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
HSP90AA1 P07900 1/20 0.52
KMT2A Q03164 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
MEN1 O00255 3/20 0.51
POLB P06746 1/20 0.51
CLK1 P49759 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C19 P33261 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL544192 0.93 CASP3 (0.60) LCKCASP3SENP8SENP7SENP6
SCHEMBL544513 0.87 CASP3 (0.62) LCKCASP3SENP8SENP7SENP6
SCHEMBL544677 0.85 ABL1 (0.58) CASP3SENP8SENP7SENP6ABL1
SCHEMBL544856 0.83 TUBB4A (0.64) MAPTHTTLMNANPC1RAB9A
SCHEMBL544152 0.83 GHSR (0.53) LCKABL1MAPTNPC1RAB9A
SCHEMBL544342 0.82 RAB9A (0.61) LCKCASP3SENP8SENP7SENP6
SCHEMBL544638 0.82 GHSR (0.60) MAPTHTTLMNANPC1RAB9A
SCHEMBL544180 0.79 ABL1 (0.56) LCKABL1MAPTHTTLMNA
SCHEMBL544973 0.79 CYP3A4 (0.49) MAPTHTTLMNANPC1RAB9A
SCHEMBL544395 0.79 ALDH1A1 (0.62) MAPTHTTLMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110571-B2 Tyrosine kinase inhibitors; antiproliferation agents; metabolism diseases; antiallergens; central nervous system disorders; vision and skin disorders; antiarthritic agents AVENTIS PHARMA S.A. (FR) 2012-02-07 US disclosed
US-20080194555-A1 Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors AVENTIS PHARMA S.A. (FR) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194555-A1 Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors MET, KIT, MERTK LCK 503/4885CASP3 2704/4885SENP8 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.